AlphAIalphai — Financial news for AI agents
ts2.techSEP 42 min read$IONS

Ionis Stock Loses $877 Million After Pelacarsen Phase 3 Miss

Ionis Pharmaceuticals (IONS) lost $877 million in market value after its heart drug, pelacarsen, failed a Phase 3 trial. Shares dropped 9.1% to $52.81, and Novartis (NVS) also saw a 5.0% decline. The drug reduced Lp(a) but did not lower cardiovascular events. Ionis retains 75% of future royalties, with Royalty Pharma owning the rest.

Original reporting
ts2.tech
Published Sep 4, 2026, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 5, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Ionis Stock Loses $877 Million After Pelacarsen Phase 3 Miss — source image
Source · ts2.tech
Decision brief

The 30-second read

$IONSBearishHigh
01

Why it matters

The miss erodes expected future royalty payments, reduces market cap, and may affect other Lp(a) programs.

02

Market read

Immediate after‑hours price drops for Ionis (‑9.1%) and Novartis (‑5%) reflect the market's reaction to the failed Phase 3 trial.

03

What to watch

Ionis still holds cash and other products; the miss may be priced in, offering a potential value entry at lower levels.

Relevance 9/10Novelty 9/10Timing: after‑hours Sep 4 2026

Background

Ionis discovered pelacarsen, licensed it to Novartis, and earned royalty upside contingent on approval; the trial failure impacts both companies' royalty streams.

Company-level read

Ticker impact

$IONSBearishHigh confidence
Context

Ionis shares fell 9.1% after its Phase 3 pelacarsen trial missed the primary endpoint, wiping $877 million of market value.

Expected impact

Further downside risk if no remedial data emerges; short‑term bounce possible on broader market support.

Evidence & confidence

The trial result is a primary disclosure with a double‑digit move; traders can act on the immediate sell‑off.

$NVSBearishMedium confidence
Context

Novartis shares fell an additional 5% after hours as co‑developer of pelacarsen, reflecting exposure to the same trial failure.

Expected impact

Potential modest further decline if market links the miss to broader pipeline; limited upside unless clarification is provided.

Evidence & confidence

Novartis impact is secondary but still material; the move is less pronounced than Ionis.

Market effects

Sector

Biotech sector may see heightened scrutiny of Lp(a)‑targeting programs.

Regional

U.S. biotech stocks could face short‑term pressure.

Global

International partners in antisense therapeutics may see valuation adjustments.

Counterpoint

What could challenge this read

The trial showed strong Lp(a) reduction; a subset analysis could reveal a viable niche, supporting a rebound trade.

Key entities

  • company
    Ionis Pharmaceuticals

    US‑listed biotech developing antisense therapies.

  • company
    Novartis AG

    Swiss pharma partner and co‑developer of pelacarsen.

Read at source← All news

Related articles

SEP 5
$NVSMedAI 8/10

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Novartis and Ionis' RNA drug, pelacarsen, failed to reduce heart attack, stroke, and death risks in a Phase 3 trial, despite lowering Lp(a) levels. Novartis stated the results were disappointing but may inform future cardiovascular approaches. Analysts noted the failure raises questions about similar therapies and potential impacts on ongoing trials. The drug was expected to generate significant revenue if successful.

biopharmadive.com2 min
SEP 5
$NVSHighAI 9/10

Novartis, Ionis’ experimental heart drug misses key goal in trial

Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.

manilatimes.net2 min
SEP 5
$NVSHighAI 8/10

Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial

Novartis' phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint, as the drug did not reduce cardiovascular events compared to placebo, despite lowering Lp(a) levels. The company acknowledged the results were not as hoped but may advance scientific understanding. NVS shares closed at $159.99, down 1.90%, and rose to $162.90 in afterhours trading.

rttnews.com2 min
SEP 5
$NVSMedAI 8/10

Novartis announces Phase III trial miss for pelacarsen

Novartis reported that its Phase III trial for pelacarsen failed to meet the primary endpoint of reducing cardiovascular events. While the drug lowered lipoprotein (a) levels, it did not significantly improve outcomes compared to placebo. Elevated Lp(a) is a risk factor for cardiovascular disease affecting 20% of the global population, with no approved treatments.

thepharmaletter.com2 min
SEP 5
$IONSHighAI 8/10

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Ionis Pharmaceuticals (IONS) shares rose 4% after-hours following FDA approval for Tryngolza in severe hypertriglyceridemia. Goldman Sachs raised its price target to $75, maintaining a 'Neutral' rating. The drug showed significant triglyceride reduction and pancreatitis risk reduction in trials. Ionis plans a July U.S. launch. Analysts' average price target is $104.91, suggesting 37% upside from Wednesday's close.

stocktwits.com2 min